Satsuma Pharmaceuticals

YTD

ALL

Why Robinhood?

You can watch STSA and buy or sell other stocks, options, and ETFs commission-free!

About STSA

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

CEO

Ryoichi Nagata, MD, PhD

CEORyoichi Nagata, MD, PhD

Employees

—

Employees—

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

2016

Founded2016

Employees

—

Employees—

STSA Key Statistics

Market cap

36.47M

Market cap36.47M

Price-Earnings ratio

-0.55

Price-Earnings ratio-0.55

Dividend yield

—

Dividend yield—

Average volume

412.49K

Average volume412.49K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$8.08

52 Week high$8.08

52 Week low

$0.59

52 Week low$0.59